Avenue Therapeutics, Inc. ATXI

Avenue Therapeutics, Inc. (ATXI) entered an exclusive worldwide license agreement for ATX-04, a novel therapy targeting Pompe Disease, a rare genetic disorder. Exclusive worldwide licensing of ATX-04 for Pompe Disease represents a major pipeline expansion that could significantly enhance ATXI's growth prospects and investor interest.

Avenue Therapeutics, Inc. announced that its subsidiary, Baergic Bio, has been acquired by Axsome Therapeutics. This acquisition is part of Axsome's strategy to enhance its portfolio in the central nervous system space. The deal is expected to leverage Baergic Bio's innovative approaches to treatment, potentially benefiting both companies in their future endeavors. The acquisition of Baergic Bio by Axsome Therapeutics represents a significant strategic move that could enhance Avenue Therapeutics' market position and investor sentiment.

Insiders of Avenue Therapeutics, Inc. face losses as stock price drops by 29%. Insider transactions and stock price decrease may moderately influence the company's future.

Nasdaq announced the delisting of Avenue Therapeutics, Inc. (ATXI) along with several other companies due to their securities being suspended for trading. Avenue Therapeutics' stock was suspended on March 19, 2025, and has not traded since. The delisting affects the common stock of ATXI, which is part of a broader trend of suspensions and delistings across various companies. The delisting of Avenue Therapeutics from Nasdaq is likely to significantly impact its market performance and investor sentiment.

Avenue Therapeutics reports third quarter 2024 financial results and recent corporate highlights. The financial results and corporate highlights may moderately influence key areas such as financial performance and competitive positioning.

Avenue Therapeutics CEO to participate in Maxim Group's Healthcare Virtual Summit on October 15, 2024. Participation in the summit may moderately influence Avenue Therapeutics' competitive positioning and market sentiment.

Avenue Therapeutics, Inc. announced CEO's participation in upcoming investor conferences. Participation in investor conferences may moderately influence financial performance and competitive positioning.

Fortress Biotech, Inc. reports financial results and recent corporate highlights for the second quarter of 2024, including regulatory updates, clinical updates, and other business developments. Significant impact expected on Avenue Therapeutics, Inc. future and market performance due to potential regulatory approvals and clinical advancements.

Avenue Therapeutics reported Q2 2024 financial results and progress in Phase 1b/2a trial of AJ201 for SBMA. Raised $4.4 million in May 2024. Completion of Phase 1b/2a trial and progress in developing novel treatments expected to significantly impact future performance.

Avenue Therapeutics, Inc. will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference. Presentation at a key conference may influence competitive positioning and product innovation.

Avenue Therapeutics completes Phase 1b/2a clinical trial of AJ201 for SBMA, with topline results expected mid-2024. Completion of clinical trial and potential for impactful therapy development could significantly alter company's trajectory.

Avenue Therapeutics reported financial results and recent corporate highlights for the first quarter of 2024, including progress on their CNS treatments pipeline and fundraising efforts. The article highlights significant advancements in Avenue Therapeutics' pipeline and financial position, indicating a potentially significant impact on the company's future performance.

Avenue Therapeutics announced the exercise of warrants for $4.4 million in gross proceeds. The exercise of warrants for $4.4 million is a significant financial move that could impact Avenue Therapeutics' future trajectory and market performance.

Avenue Therapeutics, Inc. announces a 1-for-75 reverse stock split to comply with Nasdaq's minimum bid price requirement. The reverse stock split is expected to have a moderately noticeable influence on the company's financial performance and market positioning.

Avenue Therapeutics to host virtual KOL event on April 4, 2024 for SBMA treatment with AJ201. The event may have a significant impact on Avenue Therapeutics' future based on potential outcomes of the Phase 1b/2a trial and expert perspectives on SBMA treatment.

Avenue Therapeutics reports full year 2023 financial results and recent corporate highlights, including completion of enrollment in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy, positive preclinical data for BAER-101, and final agreement with FDA on study design for Phase 3 safety study of IV tramadol. The completion of enrollment in Phase 1b/2a clinical trial, positive preclinical data, and final agreement with FDA on study design for Phase 3 safety study are significant developments that could impact Avenue Therapeutics' future performance.

Avenue Therapeutics to present BAER-101 preclinical data at ASENT 2024 Annual Meeting. The presentation of preclinical data at a major neurotherapeutics meeting could moderately influence Avenue Therapeutics' competitive positioning and product innovation.

Avenue Therapeutics announces publication of preclinical data on BAER-101 in absence epilepsy model. The publication of preclinical data on BAER-101's ability to suppress seizures without adverse effects could significantly impact the company's future development and market performance.

Avenue Therapeutics to present at Sidoti January Micro-Cap Investor Conference. Presentation at investor conference may moderately influence financial performance and competitive positioning.

Avenue Therapeutics enters into warrant exercise agreements with investors for $5.0 million in proceeds. The warrant exercise transactions are expected to have a moderately noticeable influence on Avenue Therapeutics' financial performance and competitive positioning.

Avenue Therapeutics finalizes Phase 3 safety study agreement with FDA for IV Tramadol. The Phase 3 study outcome could potentially lead to FDA approval of IV Tramadol, significantly impacting Avenue Therapeutics' future and market performance.

Avenue Therapeutics completes enrollment in Phase 1b/2a clinical trial of AJ201 for SBMA, with topline data expected in Q2 2024. Completion of enrollment in a key clinical trial with potential for significant impact on future drug development and market positioning.

Avenue Therapeutics to present preclinical data on BAER-101 for absence epilepsy at AES 2023 Annual Meeting. Presentation of promising preclinical data on BAER-101 with potential to address unmet needs in epilepsy patients.

Avenue Therapeutics reports Q3 financial results and recent corporate highlights, including progress on clinical trials, preclinical data presentation, FDA agreement, and fundraising. The news article highlights significant developments in clinical trials, preclinical data, FDA agreement, and fundraising, which are expected to have a significant impact on Avenue Therapeutics' future and market performance.

Avenue Therapeutics priced a $5.0 million public offering of 16,633,400 units. The public offering may have a moderately noticeable influence on Avenue Therapeutics' financial performance and competitive positioning.

Avenue Therapeutics to present corporate update at H.C. Wainwright 25th Annual Global Investment Conference. The presentation at the conference may influence key areas like financial performance and competitive positioning.

Fortress Biotech reports strong financial results and positive clinical data for various late-stage assets, including DFD-29 and cosibelimab. The positive clinical data and upcoming NDA submissions for key assets are expected to have a significant impact on Avenue Therapeutics' future performance.

Avenue Therapeutics reports second quarter 2023 financial results and recent corporate highlights, including dosing first patient in Phase 1b/2a clinical trial of AJ201, positive preclinical data for BAER-101, and agreement with FDA on Phase 3 safety study design for IV tramadol. Significant impact expected on Avenue Therapeutics' future with advancements in clinical trials and regulatory agreements.

BAER-101, a GABA-A receptor potentiator, shows high potency and efficacy in a model of generalized seizures, supporting Phase 2 clinical study. The potential of BAER-101 to improve epilepsy treatment with increased tolerability, potency, and efficacy could significantly impact Avenue Therapeutics' future and market performance.